Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved

Author(s):  Allen Loyd V Jr

Issue:  Jan/Feb 2020 - Volume 24, Number 1
View All Articles in Issue

Page(s):  44-50

Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved Page 1
Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved Page 2
Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved Page 3
Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved Page 4
Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved Page 5
Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved Page 6
Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved Page 7

Download in electronic PDF format for $65

Abstract:  Intravenous admixture compounding requires a knowledge of stability, compatibility, and incompatibility issues related to the complete composition and formulation of the admixture. Referring to tables, charts, etc. is valuable but not always sufficient to determine whether or not a specific intravenous admixture will be stable and compatible. In evaluating an intravenous admixture, one is not just concerned with the active ingredients but with all the excipients. Excipients used in the formulations of commercially available products may vary between manufacturers, and these variations can influence drug compatibility and stability. Clinical pharmaceutics involves the study and application or pharmaceutics to real-life clinical compounding situations to aid in the evaluation of each intravenous admixture. This series continues with compatibility considerations in intravenous admixture compounding and will cover most aspects of the issues involved, to include in-syringe admixtures and small-volume and large-volume admixtures.

Related Keywords: Loyd V. Allen, Jr., PhD, RPh, intravenous drug admixtures, compounded sterile preparations, stability, compatibility, incompatibility, excipients, syringes, small-volume parenteral formulations, large-volume parenteral formulations, cosolvent formulations, pH, solubility, concentration, complexation, light, temperature, vehicle, drug sorption, drug adsorption, drug absorption, drug containers, polyvinyl chloride, PVC, drug interactions

Related Categories: EXCIPIENTS, PACKAGING, PARENTERALS, STABILITIES, COMPATIBILITIES, STERILE PREPARATIONS, QUALITY CONTROL

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved
Allen Loyd V Jr
Jan/Feb 2020
Pg. 44-50

Intravenous Admixture Preparation Considerations, Part 9-A: Error Prevention in Intravenous Admixture Preparation
Allen Loyd V Jr
Mar/Apr 2021
Pg. 131-139

Intravenous Admixture Preparation Considerations, Part 3: Methods and Techniques to Decrease Incompatibilities
Allen Loyd V Jr
Mar/Apr 2020
Pg. 121-126

Intravenous Admixture Preparation Considerations, Part 9-B: Error Prevention in Intravenous Admixture Preparation
Allen Loyd V Jr
May/Jun 2021
Pg. 222-229

Sterile Basics: Intravenous Admixture Preparation Considerations, Part 5: pH Considerations
Allen Loyd V Jr
Jul/Aug 2020
Pg. 305-309

Intravenous Admixture Preparation Considerations, Part 1: Overview of Series on Personnel Selection for Intravenous Admixture Compounding
Allen Loyd V Jr
Nov/Dec 2019
Pg. 478-482

Intravenous Admixture Preparation Considerations, Part 7: Stability Issues
Allen Loyd V Jr
Nov/Dec 2020
Pg. 473-478

Intravenous Admixture Preparation Considerations, Part 8: Ready-to-Use Preparations
Allen Loyd V Jr
Jan/Feb 2021
Pg. 31-38

Basics of Sterile Compounding: Intravenous Admixture Preparation Considerations, Part 10: Packaging and Container-closure Issues
Allen Loyd V Jr
Jul/Aug 2021
Pg. 311-317

Sterile Basics: Intravenous Admixture Compounding, Part 1: Introduction and Overview of the General Guidelines for an Intravenous Admixture Compounding Program, and Compounding Personnel Considerations
Allen Loyd V Jr
Mar/Apr 2023
Pg. 123-139

Sterile Basics: Intravenous Admixture Preparation Considerations, Part 4: Particulates
Allen Loyd V Jr
May/Jun 2020
Pg. 215-220

Intravenous Admixture Preparation Considerations, Part 6: pH Considerations -- Applications
Allen Loyd V Jr
Sep/Oct 2020
Pg. 397-402

Sterile Basics: Intravenous Admixture Compounding, Part 2: Parenteral Vehicle Considerations
Allen Loyd V Jr
May/Jun 2023
Pg. 223-229

Basics of Sterile Compounding: Intravenous Admixture Preparation, Part 12: United States Pharmacopeia Chapters Referenced in the Current United States Pharmacopeia Chapter <797> Pharmaceutical Compounding -- Sterile Preparations
Allen Loyd V Jr
Nov/Dec 2021
Pg. 491-496

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Basics of Sterile Compounding: Intravenous Admixture Preparation, Part 11: Particulate Issues --- Silicone Oil in Vials, Cartridges, and Syringes
Allen Loyd V Jr
Sep/Oct 2021
Pg. 403-408

Zinc Content of Commercial Diluents Widely Use in Drug Admixtures Prepared for Intravenous Infusion
Desai Narendra R
, Shah Syed M, Koczone Julianna, Vencl-Joncic Maja, Sisto Christopher, Ludwig Stephen A
Sep/Oct 2007
Pg. 426-432

Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration
Lu Juan
, Liu Qiang, Kupiec Thomas C, Vail Herbert, Lynch Leslie R, Fam David S, Vu Nicole T
Jan/Feb 2021
Pg. 52-61

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Intravenous Physical Compatibility of Heparin Sodium and Furosemide
Maktabi Briana
, Howard Mitchell S, Baki Gabriella, Churchwell Mariann D
Nov/Dec 2022
Pg. 522-526